ethyl (E)-2-(4-(3-(3-formyl-4-hydroxy-5-methylphenyl)acryloyl)phenoxy)-2-methylpropanoate | 1444002-61-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: ethyl (E)-2-(4-(3-(3-formyl-4-hydroxy-5-methylphenyl)acryloyl)phenoxy)-2-methylpropanoate
• CAS: 1444002-61-2
• 化学式: C₂₃H₂₄O₆
• 分子量: 396.44
• InChiKey: COOCOGDFBADMLN-IZZDOVSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.13
• 重原子数：
  29.0
• 可旋转键数：
  8.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  89.9
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  ethyl (E)-2-(4-(3-(3-formyl-4-hydroxy-5-methylphenyl)acryloyl)phenoxy)-2-methylpropanoate 、 丙二酸二乙酯 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以75%的产率得到(E)-ethyl 6-(3-(4-(1-ethoxy-2-methyl-1-oxopropan-2-yloxy)phenyl)-3-oxoprop-1-enyl)-8-methyl-2-oxo-2H-chromene-3-carboxylate
  参考文献：
  名称：

  Coumarin chalcone fibrates: A new structural class of lipid lowering agents

  摘要：

  In our continuing search for safe and efficacious antidyslipidemic agents, structurally interesting coumarin-chalcone fibrates were synthesized and evaluated in triton WR-1339 induced hyperlipidemic rats. The most active compound 41 decreased the total cholesterol (TC), phospholipids (PL) and triglycerides (TG), of hyperlipidemic rats by 26, 24, and 25% respectively. In addition, the compound 41 significantly reversed the levels of VLDL, LDL HDL and also increased the LPL activity. Altogether, our data suggests that these novel hybrids would be a potential new class of therapeutic agents against dyslipidemia. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.026
• 作为产物：
  描述：

  2-溴-2-甲基丙酸乙酯 在 盐酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 4.0h， 生成 ethyl (E)-2-(4-(3-(3-formyl-4-hydroxy-5-methylphenyl)acryloyl)phenoxy)-2-methylpropanoate
  参考文献：
  名称：

  Coumarin chalcone fibrates: A new structural class of lipid lowering agents

  摘要：

  In our continuing search for safe and efficacious antidyslipidemic agents, structurally interesting coumarin-chalcone fibrates were synthesized and evaluated in triton WR-1339 induced hyperlipidemic rats. The most active compound 41 decreased the total cholesterol (TC), phospholipids (PL) and triglycerides (TG), of hyperlipidemic rats by 26, 24, and 25% respectively. In addition, the compound 41 significantly reversed the levels of VLDL, LDL HDL and also increased the LPL activity. Altogether, our data suggests that these novel hybrids would be a potential new class of therapeutic agents against dyslipidemia. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.026